TRAIL of Hope Meeting Resistance in Cancer

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Ralff, 2018, TRAIL pathway targeting therapeutics, Expert Rev. Precis. Med. Drug Dev., 3, 197, 10.1080/23808993.2018.1476062 Josephs, 2018, Unleashing endogenous TNF-alpha as a cancer immunotherapeutic, J. Transl. Med., 16, 242, 10.1186/s12967-018-1611-7 Walczak, 1999, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat. Med., 5, 157, 10.1038/5517 Ashkenazi, 1999, Safety and antitumor activity of recombinant soluble Apo2 ligand, J. Clin. Invest., 104, 155, 10.1172/JCI6926 Stuckey, 2013, TRAIL on trial: preclinical advances in cancer therapy, Trends Mol. Med., 19, 685, 10.1016/j.molmed.2013.08.007 Guimarães, 2018, Nanoparticles for immune cytokine TRAIL-based cancer therapy, ACS Nano, 12, 912, 10.1021/acsnano.7b05876 Wang, 2015, Nanoparticle-mediated target delivery of TRAIL as gene therapy for glioblastoma, Adv. Healthc. Mater., 4, 2719, 10.1002/adhm.201500563 Ke, 2017, Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells, Int. J. Nanomedicine, 12, 2531, 10.2147/IJN.S129274 Hu, 2015, Nanoparticle biointerfacing by platelet membrane cloaking, Nature, 526, 118, 10.1038/nature15373 Mitchell, 2015, Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis, Nat. Commun., 8, 14179, 10.1038/ncomms14179 Ren, 2015, Peptide GE11–polyethylene glycol-polyethylenimine for targeted gene delivery in laryngeal cancer, Med. Oncol., 32, 185, 10.1007/s12032-015-0624-9 De Miguel, 2016, High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer, Cancer Lett., 383, 250, 10.1016/j.canlet.2016.10.005 Nair, 2015, Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display, Proc. Natl. Acad. Sci. U. S. A., 112, 5679, 10.1073/pnas.1418962112 Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 7, 6387 Stein, 2017, First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors, Clin. Cancer Res., 23, 4163, 10.1158/1078-0432.CCR-16-2658 Allen, 2012, Targeting TRAIL death receptor 4 with trivalent DR4 atrimer complexes, Mol. Cancer Ther., 11, 2087, 10.1158/1535-7163.MCT-12-0366 Twomey, 2015, Spatial dynamics of TRAIL death receptors in cancer cells, Drug Resist. Updat., 19, 13, 10.1016/j.drup.2015.02.001 Haselmann, 2014, Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells, Gastroenterology, 1, 278, 10.1053/j.gastro.2013.10.009 Reis, 2017, TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation, Proc. Natl. Acad. Sci. U. S. A., 114, 504, 10.1073/pnas.1615072114 Zhu, 2016, Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer, Cancer Lett., 383, 154, 10.1016/j.canlet.2016.09.021 Lu, 2013, Targeting microRNAs to modulate TRAIL-induced apoptosis of cancer cells, Cancer Gene Ther., 20, 33, 10.1038/cgt.2012.81 O’Leary, 2015, Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity, Oncogene, 35, 1261, 10.1038/onc.2015.180 Irmler, 1997, Inhibition of death receptor signals by cellular FLIP, Nature, 388, 190, 10.1038/40657 Crowder, 2012, Caspase-8 regulation of TRAIL-mediated cell death, Exp. Oncol., 34, 160 Jin, 2009, Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling, Cell, 137, 721, 10.1016/j.cell.2009.03.015 Bellail, 2012, A20 Ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma, Cancer Discov., 2, 140, 10.1158/2159-8290.CD-11-0172 Powley, 2016, Caspase-8 tyrosine-380 phosphorylation inhibits CD95 DISC function by preventing procaspase-8 maturation and cycling within the complex, Oncogene, 35, 5629, 10.1038/onc.2016.99 Zhang, 2018, Targeting CDK1 and MEK/ERK Overcomes apoptotic resistance in BRAF-mutant human colorectal cancer, Mol. Cancer Res., 16, 378, 10.1158/1541-7786.MCR-17-0404 Haag, 2011, Identification of c-FLIPL and c-FLIPS as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells, Gut, 60, 225, 10.1136/gut.2009.202325 McLornan, 2010, Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer, Clin. Cancer Res., 16, 3442, 10.1158/1078-0432.CCR-10-0052 McCourt, 2012, Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy, Clin. Cancer Res., 18, 3822, 10.1158/1078-0432.CCR-11-3277 Golks, 2006, The c-FLIP-NH2 terminus (p22-FLIP) induces NFκB activation, J. Exp. Med., 203, 1295, 10.1084/jem.20051556 Nakajima, 2006, An antiapoptotic protein, c-FLIPL, directly binds to MKK7 and inhibits the JNK pathway, EMBO J., 25, 5549, 10.1038/sj.emboj.7601423 Xiao, 2005, Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis, Exp. Cell Res., 304, 244, 10.1016/j.yexcr.2004.11.002 Higuchi, 2003, Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis, J. Biol. Chem., 278, 454, 10.1074/jbc.M209387200 Trivedi, 2015, Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells, Front. Oncol., 5, 69, 10.3389/fonc.2015.00069 Hari, 2015, Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL, Oncotarget, 6, 41902, 10.18632/oncotarget.5881 Stilgenbauer, 2016, Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study, Lancet Oncol., 17, 768, 10.1016/S1470-2045(16)30019-5 Tolcher, 2015, Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors, Cancer Chemother. Pharmacol., 76, 1025, 10.1007/s00280-015-2883-8 Park, 2013, Down-regulation of survivin by nemadipine-A sensitizes cancer cells to TRAIL-induced apoptosis, Biomol. Ther., 21, 29, 10.4062/biomolther.2012.088 Saraei, 2018, The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in leukemia, Biomed. Pharmacother., 107, 1010, 10.1016/j.biopha.2018.08.065 Benitez, 2017, PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3, Nat. Commun., 8, 15223, 10.1038/ncomms15223 Xu, 2010, Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells, PLoS One, 5 von Karstedt, 2015, Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis, Cancer Cell, 27, 561, 10.1016/j.ccell.2015.02.014 Azijli, 2012, Kinome profiling of non-canonical TRAIL signaling reveals RIP1–Src–STAT3-dependent invasion in resistant non-small cell lung cancer cells, J. Cell Sci., 125, 4651 Di, 2013, Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5, Oncotarget, 4, 1349, 10.18632/oncotarget.1174 de Looff, 2019, Multiple interactions between cancer cells and the tumor microenvironment modulate TRAIL signaling: implications for TRAIL receptor targeted therapy, Front. Immunol., 10, 1530, 10.3389/fimmu.2019.01530 Kumar Hira, 2014, Downregulation of endogenous STAT3 augments tumoricidal activity of interleukin 15 activated dendritic cell against lymphoma and leukemia via TRAIL, Exp. Cell Res., 327, 192, 10.1016/j.yexcr.2014.08.012 Liguori, 2016, Functional TRAIL receptors in monocytes and tumor-associated macrophages: a possible targeting pathway in the tumor microenvironment, Oncotarget, 7, 41662, 10.18632/oncotarget.9340 Zou, 2017, IL-35 induces N2 phenotype of neutrophils to promote tumor growth, Oncotarget, 8, 33501, 10.18632/oncotarget.16819 Fingas, 2011, Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells, Hepatology, 54, 2076, 10.1002/hep.24588 Hartwig, 2017, The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2, Mol. Cell, 65, 730, 10.1016/j.molcel.2017.01.021 Kretz, 2019, TRAILblazing strategies for cancer treatment, Cancers, 11, 456, 10.3390/cancers11040456 Willms, 2019, Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells, PLoS One, 14, 10.1371/journal.pone.0214847 Singh, 2016, Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer, Carcinogenesis, 37, 1027, 10.1093/carcin/bgw088 Su, 2007, 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF alpha-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling, Mol. Cancer Ther., 6, 1562, 10.1158/1535-7163.MCT-06-0800 Elmallah, 2019, Epigenetic regulation of TRAIL signaling: implication for cancer therapy, Cancers, 11, 850, 10.3390/cancers11060850 Gillespie, 2006, Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells, Apoptosis, 11, 2251, 10.1007/s10495-006-0283-6 Facchetti, 2004, Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors, Apoptosis, 9, 573, 10.1023/B:APPT.0000038036.31271.50 Chueh, 2017, ATF3 repression of BCL-XL determines apoptotic sensitivity to HDAC inhibitors across tumor types, Clin. Cancer Res., 23, 5573, 10.1158/1078-0432.CCR-17-0466 Straszewski-Chavez, 2007, XAF1 mediates tumor necrosis factor-alpha-induced apoptosis and X-linked inhibitor of apoptosis cleavage by acting through the mitochondrial pathway, J. Biol. Chem., 282, 13059, 10.1074/jbc.M609038200 Imai, 2006, Comparing antibody and small-molecule therapies for cancer, Nat. Rev. Cancer, 6, 714, 10.1038/nrc1913 Zhu, 2017, Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors, Sci. Rep., 7, 2602, 10.1038/s41598-017-02483-9 Choi, 2015, Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas, Mol. Ther., 23, 235, 10.1038/mt.2014.214 Booth, 2009, A cell-based high-throughput screen to identify synergistic TRAIL sensitizers, Cancer Immunol. Immunother., 58, 1229, 10.1007/s00262-008-0637-8 Taylor, 2011, Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells, BMC Cancer, 11, 470, 10.1186/1471-2407-11-470 Lemke, 2014, Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1, Cell Death Differ., 21, 491, 10.1038/cdd.2013.179 Menke, 2011, Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents, Cancer Res., 71, 1883, 10.1158/0008-5472.CAN-10-2252 Beyer, 2019, Interactions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with the immune system: implications for inflammation and cancer, Cancers, 11, 1161, 10.3390/cancers11081161 Hendriks, 2016, Programmed death ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction, OncoImmunology, 5, 10.1080/2162402X.2016.1202390 de Bruyn, 2011, Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells, Clin. Cancer Res., 17, 5626, 10.1158/1078-0432.CCR-11-0303 Wiersma, 2015, C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity, mAbs, 7, 321, 10.1080/19420862.2015.1007811 Song, 2016, Secretory TRAIL-armed natural killer cell-based therapy: in vitro and in vivo colorectal peritoneal carcinomatosis xenograft, Mol. Cancer Ther., 15, 1591, 10.1158/1535-7163.MCT-15-0937 Gieffers, 2013, APG350 Induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fc receptors, Mol. Cancer Ther., 12, 2735, 10.1158/1535-7163.MCT-13-0323 Lemke, 2014, Getting TRAIL back on track for cancer therapy, Cell Death Differ., 21, 1350, 10.1038/cdd.2014.81 Cheah, 2015, Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study, Lancet Haematol., 2, e166, 10.1016/S2352-3026(15)00026-5 Kelley, 2005, Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling, J. Biol. Chem., 280, 2205, 10.1074/jbc.M410660200 MacFarlane, 2005, TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies, Cancer Res., 65, 11265, 10.1158/0008-5472.CAN-05-2801 Lemke, 2010, TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5, J. Mol. Med. (Berl.), 88, 729, 10.1007/s00109-010-0619-0 Belch, 2010, A multicenter randomized phase ii trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with bortezomib in patients with relapsed/refractory multiple myeloma (MM), Blood, 116, A5031, 10.1182/blood.V116.21.5031.5031 Fuchs, 2013, TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: a randomized phase 1b/2 trial, Cancer, 119, 4290, 10.1002/cncr.28353 Merchant, 2012, Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors, J. Clin. Oncol., 30, 4141, 10.1200/JCO.2012.44.1055 Reck, 2013, A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer, Lung Cancer, 82, 441, 10.1016/j.lungcan.2013.09.014 Ratain, 2019, Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621, J. Clin. Oncol., 37, 3013, 10.1200/JCO.2019.37.15_suppl.3013 Niemoeller, 2013, Radiotherapy and TRAIL for cancer therapy, Cancer Lett., 332, 184, 10.1016/j.canlet.2011.07.003 Zhao, 2012, Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells, Cancer Lett., 314, 8, 10.1016/j.canlet.2011.09.040 Wong, 2019, The TRAIL to cancer therapy: hindrances and potential solutions, Crit. Rev. Oncol. Hematol., 143, 81, 10.1016/j.critrevonc.2019.08.008 Ricci, 2007, Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death, Cancer Cell, 12, 66, 10.1016/j.ccr.2007.05.006 Katz, 2009, Sorafenib inhibits ERK1/2 and MCL-1L phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma, Cancer Biol. Ther., 8, 2406, 10.4161/cbt.8.24.10824 Puduvalli, 2005, TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation, Apoptosis, 10, 233, 10.1007/s10495-005-6078-3